Document Detail


Carboplatin and hypofractionated accelerated radiotherapy: a dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neck.
MedLine Citation:
PMID:  16477924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To examine the feasibility and determine the maximum tolerated dose of outpatient carboplatin given with synchronous hypofractionated accelerated radiotherapy for squamous cell carcinoma of the head and neck (SCCHN). MATERIALS AND METHODS: Patients with stages II-IV SCCHN and unresected primary tumour were treated with synchronous carboplatin given in an outpatient setting on day 1 and day 21 in cohorts of three to six patients with incremental area under curve (AUC) factors commencing at 3.5. Grade 3 mucositis persisting for 4 weeks in two patients in a cohort was considered dose limiting. RESULTS: A total of 19 patients were enrolled and assessable for toxicity. All 19 patients completed 55 Gy of radiotherapy and were assessable for response. Grade 3 mucositis lasting 4 weeks or more was seen in three patients, two of them received AUC 5 carboplatin. A complete response was seen in 16 patients, with a further patient having a partial response, giving a response rate of 89%. With a median follow-up of 24 months (range 11-30 months), 13 patients were alive with no evidence of recurrent disease. Local recurrence had occurred in four patients with distant spread in three patients. CONCLUSION: Carboplatin with concurrent hypofractionated accelerated radiotherapy is feasible for patients with advanced SCCHN and good performance status. The recommended phase II dose of carboplatin given in week 1 and week 4 with 55 Gy in 20 fractions is AUC 4.5.
Authors:
K Madhava; A Hartley; M Wake; J C Watkinson; J Glaholm
Related Documents :
1569444 - Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian canc...
2655094 - Optimal dosing with carboplatin.
9445194 - Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma m...
18978564 - Phase ii study of paclitaxel, carboplatin, and cetuximab as first line treatment, for p...
10928394 - Granulocyte colony-stimulating factor use in cancer patients.
18320284 - Surgical treatment of hepatocellular carcinoma beyond milan criteria. results of liver ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical oncology (Royal College of Radiologists (Great Britain))     Volume:  18     ISSN:  0936-6555     ISO Abbreviation:  Clin Oncol (R Coll Radiol)     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-15     Completed Date:  2006-05-02     Revised Date:  2008-03-10    
Medline Journal Info:
Nlm Unique ID:  9002902     Medline TA:  Clin Oncol (R Coll Radiol)     Country:  England    
Other Details:
Languages:  eng     Pagination:  77-81     Citation Subset:  IM    
Affiliation:
Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Analgesics, Opioid / therapeutic use
Antineoplastic Agents / administration & dosage*,  adverse effects
Area Under Curve
Carboplatin / administration & dosage*,  adverse effects
Carcinoma, Squamous Cell / drug therapy*,  radiotherapy*
Combined Modality Therapy
Dose Fractionation*
Dose-Response Relationship, Drug
Head and Neck Neoplasms / drug therapy*,  radiotherapy*
Humans
Infusions, Intravenous
Middle Aged
Mucositis / drug therapy,  etiology
Neoplasm Recurrence, Local
Neoplasm Staging
Treatment Outcome
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 0/Antineoplastic Agents; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord comp...
Next Document:  Uncertainty of measurement: approaches and open problems.